VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 24, Issue 3, Pages 2506
Publisher
MDPI AG
Online
2023-01-30
DOI
10.3390/ijms24032506
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives
- (2022) Nora Berois et al. Cancers
- Combined Analysis of Multiple Glycan-Array Datasets: New Explorations of Protein–Glycan Interactions
- (2021) Zachary Klamer et al. ANALYTICAL CHEMISTRY
- Emerging CAR-T Cell Therapy for the Treatment of Triple Negative Breast Cancer
- (2020) Sundee Dees et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of N-linked Glycosylation by Tunicamycin May Contribute to The Treatment of SARS-CoV-2
- (2020) Ali Adel Dawood et al. MICROBIAL PATHOGENESIS
- CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia
- (2019) Dennis C. Harrer et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities–Merits and Challenges
- (2019) Dennis C. Harrer et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types
- (2018) Kristina M. Ilieva et al. Frontiers in Immunology
- Differential Expression of Cancer-Associated Fibroblast-Related Proteins in Ductal Carcinoma in situ According to Molecular Subtype and Stromal Histology
- (2018) Ji Hee Lee et al. PATHOBIOLOGY
- Inhibition of N-glycosylation by tunicamycin attenuates cell–cell adhesion via impaired desmosome formation in normal human epidermal keratinocytes
- (2018) Seon-Pil Jin et al. BIOSCIENCE REPORTS
- Chondroitin sulfate proteoglycan protein is stimulated by interleukin 11 and promotes endometrial epithelial cancer cell proliferation and migration
- (2017) Amy Winship et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects
- (2017) Laura F. Hutchins et al. Oncotarget
- Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
- (2016) Chia-Wei Li et al. Nature Communications
- Theranostic Impact of NG2/CSPG4 Proteoglycan in Cancer
- (2015) Pier Andrea Nicolosi et al. Theranostics
- Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells
- (2014) Rachel E Beard et al. Journal for ImmunoTherapy of Cancer
- T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo
- (2013) C. Geldres et al. CLINICAL CANCER RESEARCH
- CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
- (2012) Z. Rivera et al. CLINICAL CANCER RESEARCH
- CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma
- (2011) Matthew A. Price et al. Pigment Cell & Melanoma Research
- CSPG4 in Cancer: Multiple Roles
- (2010) X. Wang et al. CURRENT MOLECULAR MEDICINE
- CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer
- (2010) Xinhui Wang et al. JNCI-Journal of the National Cancer Institute
- Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies
- (2008) Allison S. Drake et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started